Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...

A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or ...

The rationale for the study, according to the authors, is that “Nearly 2% of the US population received a prescription for ...

People were able to get prescriptions easily through telehealth, and the cost was much lower than traditional prescriptions not covered by insurance. Weight loss drugs that use tirzepatide as the ...

There is also a potential increased risk for thyroid cancer, although this has only been seen in lab rats so far, not humans.

it’s essential to focus on sustainable habits that benefit your whole body — not just the number on the scale. Medications like semaglutide and tirzepatide have gained significant attention ...

Lexaria intends to add a 5th study arm - using DehydraTECH-tirzepatide in an oral capsule - to its 12-week human study already underway in Australia (study GLP-1-H24-4). In that study arm ...

GLP-1 drugs such as semaglutide and tirzepatide are at the center of a weight-loss drug revolution. The biggest development in weight-loss medicine since bariatric surgery (not to mention less ...

The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide ... same period that was not (p>0.05).